BMO Capital analyst Gary Nachman reiterated a Hold rating on Neos Therapeutics (NASDAQ: NEOS) on August 10 and set a price target of $8. The company’s shares closed on Friday at $6.25, close to its 52-week low of $5.30.
According to TipRanks.com, Nachman is a 4-star analyst with an average return of 11.3% and a 55.0% success rate. Nachman covers the Healthcare sector, focusing on stocks such as Sienna Biopharmaceuticals Inc, Bausch Health Companies Inc, and Pacira Pharmaceuticals.
Neos Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $13.
See today’s analyst top recommended stocks >>
Based on Neos Therapeutics’ latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $15.21 million. In comparison, last year the company had a GAAP net loss of $18.67 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Neos Therapeutics, Inc is a pharmaceutical company focused on developing, manufacturing and commercializing products utilizing its proprietary modified-release drug delivery technology platforms. Adzenys XR-ODT (amphetamine), Cotempla XR-ODT (methylphenidate), and Adzenys-ER (amphetamine) extended-release oral suspension, all for the treatment of ADHD, are the first three approved products using the Company’s extended-release technology platform. In addition, Neos manufactures and markets its generic version of the branded product Tussionex, an extended-release oral suspension of hydrocodone and chlorpheniramine for the relief of cough and upper respiratory symptoms of a cold. The company was founded on June 15, 2009 and is headquartered in Grand Prairie, TX.
